Why Evotec SE’s (EVO) Stock Is Up 8.92%
As of Wednesday, October 14, Evotec SE’s EVO share price has surged by 8.92%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Commentary & Analysis
Why Evotec SE’s (EVO) Stock Is Down 6.54%
As of Monday, October 12, Evotec SE’s EVO share price has dipped by 6.54%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Evotec SE’s (EVO) Stock Is Down 10.46%
As of Monday, October 12, Evotec SE’s EVO share price has dipped by 10.46%, which has investors questioning if this is right time to buy.Omar Beirat
Why Evotec SE’s (EVO) Stock Is Up 6.11%
As of Wednesday, September 02, Evotec SE’s EVO share price has surged by 6.11%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Evotec SE’s (EVO) Stock Is Down 8.22%
As of Thursday, August 13, Evotec SE’s EVO share price has dipped by 8.22%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | EVO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $614.9 | $3,763.8 | 40% |
|
| Shares Out (Mil) | 201.8 | 106.8 | 76% |
|
| Institutional Ownership | 99.4% | 89.2% | 87% |
|
| Float (Mil) | 147.0 | 83.6 | 68% |
|
| Beta | 1.31 | 1.14 | 75% |
|
| Avg Daily Volume (000s) | 81 | 1,125 | 34% |
|
| Price Change (52-week) |
(43.4%) | 86.2% | 23% |
|
| Growth | EVO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.6% | 7.5% | 53% |
|
| Net Income (5yr) | (77.8%) | (12.1%) | 3% |
|
| EPS (5yr) | (74.0%) | 2.1% | 1 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (7.9%) | (14.9%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | EVO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $816 | $811 | 47% |
|
| Net Income (TTM) (Mil) | ($205) | ($30) | 6% |
|
| EPS (TTM) | ($1.155) | ($0.300) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($104) | $52 | 6% |
|
| Net Cash Flow (TTM) (Mil) | $144 | $2 | 81% |
|
| Long-Term Debt (Q1) (Mil) | $474 | $252 | 58% |
|
| Enterprise Value (Q1) (Mil) | $731 | $3,646 | 38% |
|
| Valuation | EVO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.41 | 3.63 | 9% |
|
| P/E | na | 36.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.6 | na |
|
| Ratios | EVO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 10.3% | 47.8% | 9% |
|
| Net Margin | (25.2%) | (3.0%) | 15% |
|
| ROA | (10.8%) | (5.4%) | 24% |
|
| ROE | (24.6%) | (5.2%) | 22% |
|
| Liabilities to Assets | 57.4% | 41.5% | 51% |
|
| F-Score | 4 | 5 | 34% |
|
Evotec SE did not pass any screens on 11/12/2026.
